FTX Founder’s Defense Claims Inadequate Adderall Dosing Hinders Trial Participation; Pleads for Medication Adjustment
The attorneys representing Sam Bankman-Fried, the founder of FTX, have raised concerns about his ability to focus during his criminal trial due to inadequate dosing of his prescribed medication, Adderall. In a letter addressed to the judge on Sunday, the defense team requested a delay in the proceedings or permission to provide Bankman-Fried with his daily doses of Adderall.
According to lawyer Mark Cohen, Bankman-Fried currently receives one dose of Adderall before 6 a.m. each morning. However, this wears off well before the trial begins at 9:30 a.m., and he does not receive another dose until returning to jail in the evening. This lack of medication severely impacts his concentration and ability to actively participate in the defense’s presentation.
The defense team expressed concern about the proposed solution of giving Bankman-Fried an extended-release dose on Monday morning. They are uncertain if this will be effective and worry that jail staff may not provide the medication as required. They have attempted to resolve this issue with the Bureau of Prisons but have been unsuccessful so far.
Hot Take: FTX Founder’s Trial Hindered by Lack of Medication
The inadequate dosing of Adderall for FTX founder Sam Bankman-Fried is causing significant difficulties during his criminal trial. The defense’s plea for an adjustment in his medication has highlighted the impact it has on his ability to concentrate and actively participate in his defense. Without proper access to Adderall, Bankman-Fried struggles to focus at his usual level, hindering the preparation and presentation of his case. It remains to be seen how the court will address this issue and whether it will have a significant impact on the outcome of the trial.
By
By
By
By
By